Mechanism of Action of Aspirin Carlo Patrono, et al, N Engl J Med 2005;353:2373-83.

Slides:

Advertisements

Similar presentations

Canadian Cardiovascular Society Antiplatelet Guidelines

Advertisements

Nonsense Mutations in PCSK9 and Cardiovascular Risk Factors among 3363 Black Participants in the Study Jonathan C.Cohen, et al, N Engl J Med 2006;354:

The Long-Term Intervention with Pravastatin in Ischemic Disease (LIPID) The LIPID Study Group N Engl J Med 1998;339:

Type 2 diabetes and high blood pressure How explosive is the cocktail?

Canadian Diabetes Association 2013 Clinical Practice Guidelines Targets for Glycemic Control Chapter 8 S. Ali Imran, Rémi Rabasa-Lhoret, Stuart Ross.

STROKE STATS Third leading cause of death deaths a year strokes a year stroke survivors Leading cause of adult disability Source:

Session II: Glycemic control, when the lower is not the better Strict glycemic control and cardiovascular diseases Stefano Genovese Diabetologia e Malattie.

VBWG HPS. Lancet. 2003;361: Gæde P et al. N Engl J Med. 2003;348: Recent statin trials: Reduction in primary outcome in patients with diabetes.

Aspirin Resistance: Significance, Detection and Clinical Management of This Real Phenomenon Webcast May 10 th, 2004 Sponsored by.

The Prospective Pravastatin Pooling Project L I P I D CARECARE PPP Project Investigators Am J Cardiol 1995; 76:899–905.

WOSCOPS: West Of Scotland Coronary Prevention Study Purpose To determine whether pravastatin reduces combined incidence of nonfatal MI and death due to.

Lancet 373: , 2009 Baseline Characteristics of Participants and Study Design of Clinical Trials to Compare Intensive glucose- lowering versus.

* Based on post hoc analysis of individual outcome events (N=19,185). 1 Data on file, Sanofi Pharmaceuticals, Inc. 2 Gent M. Circulation. 1997; 96 (suppl):

Aggrenox Is it as good as the ads?. ESPS-2: European Stroke Prevention Study s Multicentre, randomized, double-blind, placebo-controlled trial s 6,602.

HOPE: Heart Outcomes Prevention Evaluation study Purpose To evaluate whether the long-acting ACE inhibitor ramipril and/or vitamin E reduce the incidence.

PPP and Complement Inhibition Clinical Trial Commentary Dr Eric Topol Chairman and Professor, Department of Cardiology Director of the Joseph J Jacobs.

The ACTIVE Investigators. N Engl J Med 2009 Apr 3 [Epub]

Antithrombotic Trialists’ Collaboration An updated collaborative overview of randomised trials of antiplatelet therapy among high-risk patients.

ANTIPLATELET TREATMENT IN PATIENTS WHO HAVE AN ISCHEMIC STROKE WHILE TAKING ASPIRIN Konstantinos Tziomalos, Stella D. Bouziana, Marianna Spanou, Stavroula.

Pocket Guide to Anticoagulation in AF & Dual Antiplatelet Therapy in ACS Rumi Jaumdally 2015 This brief presentation will summarise the recently published.

The ILLUMINATE Study: Enrollment and Outcomes Philip Barter, et al. N Engl J Med 2007;357:

Hypothesis: baseline risk status of the patients and proximity to a recent cardiovascular event influence the response to dual anti-platelet therapy. Patients.

ESPS-2: European Stroke Prevention Study s Multicentre, randomized, double-blind, placebo-controlled trial s 6,602 patients randomized within 3 months.

Predictive value of CRP vs LDL-C (i) Ridker PM, et al. N Engl J Med 2002;347: Quintile of CRP (mg/L)

The MICRO-HOPE. Microalbuminuria, Cardiovascular and Renal Outcomes in the Heart Outcomes Prevention Evaluation Reference Heart Outcomes Prevention Evaluation.

The JUPITER Trial Reference Ridker PM. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med. 2008;359:2195–2207.

Platelet activation and inhibition in polycythemia vera and essential thrombocythemia by Carlo Patrono, Bianca Rocca, and Valerio De Stefano Blood Volume.

The Use of Aspirin for Primary Prevention of Cardiovascular Diseases

Date of download: 6/21/2016 Copyright © The American College of Cardiology. All rights reserved. From: Pharmacodynamic interaction of naproxen with low-dose.

Date of download: 6/21/2016 Copyright © The American College of Cardiology. All rights reserved. From: The Multifaceted Clinical Readouts of Platelet Inhibition.

Flow Diagram of the Trial Selection Process Jeffrey S. Berger et al, JAMA. 2006;295:

Date of download: 6/21/2016 Copyright © The American College of Cardiology. All rights reserved. From: Aspirin Therapy in Primary Cardiovascular Disease.

Date of download: 6/21/2016 From: Aspirin, Statins, or Both Drugs for the Primary Prevention of Coronary Heart Disease Events in Men: A Cost–Utility Analysis.

Statins The AURORA Trial Reference Fellstrom BC. Rosuvastatin and cardiovascular events in patients undergoing hemodialysis. N Engl J Med. 2009;360. A.

Mega JL, et al. N Engl J Med 2009;360: Genetic Effects on Pharmacokinetic and Pharmacodynamic Responses to Clopidogrel Mega JL, et al. N Engl J.

Discontinuation of medication after nonfatal event: MI

Structure of Cis and Trans Fatty Acids

A. Mechanism of action of aspirin

Copyright © 2012 American Medical Association. All rights reserved.

Flow of Individuals Through the Vitamin E and Vitamin C Components of the Physicians’ Health Study II Howard D. Sesso et al. JAMA 2008;300:

LEADER trial: Primary Outcome

Effect of Aspirin Dose on Platelet Reactivity in Diabetic Patients Paul A. Gurbel, MD Director, Sinai Center for Thrombosis Research Sinai Hospital.

SOCRATES Trial design: Patients with acute ischemic stroke were randomized in a 1:1 fashion to receive either ticagrelor 180 mg load + 90 mg BID or aspirin.

Markov model structure

Pathways of thromboxane production and the antiplatelet effects of aspirin Dotted arrows denote “bypass” of aspirin’s inhibiton of platelet COX-1 Graeme.

Comparison of Triflusal and Aspirin for Prevention of Vascular Events in Patients After Cerebral Infarction by Jordi Matías-Guiu, José M. Ferro, José Alvarez-Sabín,

Timothy A. Brighton, M. B. , B. S. , John W. Eikelboom, M. B. , B. S

The following slides highlight a report on a presentation at the Late-breaking Trials Session and a Satellite Symposium of the American Heart Association.

PRECISION Trial design: Patients with arthritis and increased cardiovascular risk were randomized to celecoxib 100 mg twice daily (n = 8,072) vs. ibuprofen.

Volume 141, Issue 2, Pages e89S-e119S (February 2012)

FOURIER Trial design: Patients with established cardiovascular disease on statin therapy were randomized to evolocumab 140 mg subcutaneous every 2 weeks.

Potential mechanisms whereby statins may reduce the risk of stroke

Inclusion Criteria for Patients with Multiple Atherothrombotic Risk Factors and for Those with Established Cardiovascular Disease Deepak L.Bhatt, et al,

Volume 382, Issue 9894, Pages (August 2013)

Berger JS, et al. JAMA 2009;301:

Baseline Characteristics of the Study Participants

Baseline Characteristics of the Subjects*

Women’s Health Study: Baseline Characteristics Part 1

Age-Standardized Rates of Death from Any Cause According to the Estimated GFR among 1,120,295 Ambulatory Adults Alan S.Go et al. N Engl J Med 2004; 351:

Entry, Randomization, and Follow-up of Patients in the Hypertension in the Very Elderly Trial Of the 461 patients who did not meet the protocol criteria,

Baseline Characteristics of the Patients – Part I

Combining Antiplatelet and Antithrombotic Therapy (Triple Therapy): What Are the Risks and Benefits? Luis Alejandro Asencio, MD, Jennifer J. Huang, DO,

An ACCORD BP sub-analysis HR: 1.06; 95%CI: ; P=0.61

A Single Participant Exposed Twice to an Inflammatory Stimulus

Comparison of Baseline Characteristics by Primary End Point

EMPA-REG OUTCOME: Cumulative incidence of the primary outcome

An ACCORD BP sub-analysis HR: 1.06; 95%CI: ; P=0.61

Volume 141, Issue 2, Pages e89S-e119S (February 2012)

Section C: Clinical trial update: Oral antiplatelet therapy

Dervin Ariansyah 1. Antiplatelet Therapy Aspirin Acetysalicylic Acid Ticlopidine Clopidogrel Prasugrel Thienopyridines Cilostazol Dipyridamole Novel Agents.

Presentation transcript:

Mechanism of Action of Aspirin Carlo Patrono, et al, N Engl J Med 2005;353:

Maximal Capacity of Human Platelets to Synthesize Thromboxane B 2 (Panel A), Rate of TXB 2 Production in Healthy Subjects (Panel B), and Nonlinear Relationship between the Inhibition of Platelet Cyclooxygenase Activity and TXB 2 Biosynthesis in Vivo (Panel C) Carlo Patrono, et al, N Engl J Med 2005;353:

Absolute Effects of Antiplatelet Therapy with Aspirin on the Risk of Vascular Events (Nonfatal Myocardial Infarction, Nonfatal Stroke, or Death from Vascular Causes) in Five Groups of High-Risk Patients Carlo Patrono, et al, N Engl J Med 2005;353:

High-Risk Disorders for Which Aspirin Has Been Shown to Be Effective and Lowest Effective Daily Dose Carlo Patrono, et al, N Engl J Med 2005;353:

Benefits and Risks of Low-Dose Aspirin in Primary-Prevention Trials Carlo Patrono, et al, N Engl J Med 2005;353:

Estimated Rates of Upper Gastrointestinal Complications in Men, According to Age and the Presence or Absence of a History of Such Complications and Regular Treatment with Low-Dose Aspirin Carlo Patrono, et al, N Engl J Med 2005;353: